%0 Journal Article
%T A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
%A Dedong Cao
%A Huilin Xu
%A Tao Guo
%A Wei Ge
%A Ximing Xu
%J Archive of "Oncoimmunology".
%D 2018
%R 10.1080/2162402X.2018.1507262
%K Neutrophil-to-lymphocyte ratio
%K Nivolumab
%K immunotherapy
%K lung cancer
%K meta-analysis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205035/